NCT01335945

Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer

Percutaneous Cryoablation for the Palliation of Abdominal Pain Associated With Pancreatic Cancer

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Boston Scientific Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

CUC10-PAN09 will evaluate the safety and efficacy of cryoablation therapy on the relief of epigastric/abdominal pain associated with pancreatic cancer.

Detailed description

CUC10-PAN09 is a Supportive Care, Phase 1 multicenter, prospective, single arm study with subjects serving as their own control. This study is to enroll patients who will undergo cryoablation of the Celiac Plexus. Subjects will be followed for 3 months post their cryoablation procedure. Cryoablation is the process of destroying tissue by the application of extremely cold temperatures. Galil Medical Cryoablation Systems are used as a surgical tool in the fields of general surgery, dermatology (skin), neurology (nerves), chest surgery (including lung), Ears-Nose-Throat (ENT), gynecology, oncology (cancer), proctology (colon/rectal) and urology (kidney).

Conditions

• Pain
• Pancreatic Cancer

Interventions

Type	Name	Description
PROCEDURE	Cryoablation	All subjects will receive cryoablation of the celiac plexus with Galil Medical cryoablation systems and needles under imaging guidance.

Timeline

• Start date: 2011-08-01
• Primary completion: 2015-01-01
• Completion: 2015-01-01
• First posted: 2011-04-15
• Last updated: 2021-07-16

Locations

3 sites across 1 country: United States